OJR520 / Novartis - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jul 2027 ➔ Jan 2028 | Trial primary completion date: Jul 2027 ➔ Jan 2028

First-in-human • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease